Core Viewpoint - Rosen Law Firm is reminding investors of Zenas BioPharma, Inc. about the upcoming lead plaintiff deadline in a securities class action related to the company's IPO in September 2024 [1]. Group 1: Class Action Details - Investors who purchased Zenas BioPharma securities may be eligible for compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - A class action lawsuit has already been filed, and interested parties must move the Court by June 16, 2025, to serve as lead plaintiff [3]. - The lawsuit alleges that the Registration Statement contained false or misleading statements regarding the company's financial situation and operational funding [5]. Group 2: Rosen Law Firm's Credentials - Rosen Law Firm emphasizes the importance of selecting qualified legal counsel with a successful track record in securities class actions [4]. - The firm has achieved significant settlements, including the largest securities class action settlement against a Chinese company at the time, and has consistently ranked highly in securities class action settlements since 2013 [4]. - In 2019, the firm secured over $438 million for investors, showcasing its capability in recovering funds for clients [4].

Core Viewpoint - Zenas BioPharma, Inc. is facing a class action lawsuit due to allegations of materially false and misleading statements regarding its financial status and operational funding capabilities during its initial public offering in September 2024 [2]. Group 1: Allegations - The complaint claims that Zenas BioPharma overstated the duration it could fund its operations with existing cash and expected net proceeds from the IPO [2]. - As a result of these misstatements, the public statements made by the defendants were deemed materially false and misleading throughout the relevant period [2]. Group 2: Class Action Details - The class period for the lawsuit includes shareholders who purchased ZBIO securities during the time of the IPO registration statement and related prospectus [1]. - Shareholders are encouraged to register for the class action by June 16, 2025, to potentially be appointed as lead plaintiffs [3]. - There is no cost or obligation for shareholders to participate in the case, and they will receive updates through a portfolio monitoring software [3]. Group 3: Law Firm Background - The Gross Law Firm is a nationally recognized class action law firm dedicated to protecting investors' rights against deceit and fraud [4]. - The firm aims to ensure companies adhere to responsible business practices and seeks recovery for investors who suffered losses due to misleading statements or omissions [4].

Core Viewpoint - Zenas BioPharma, Inc. is facing a class action lawsuit due to allegations of misleading information in its IPO registration statement, particularly regarding the funding timeline for its operations [1][3][4]. Group 1: Class Action Lawsuit Details - The class action lawsuit is titled Buathongsri v. Zenas BioPharma, Inc. and is pending in the District of Massachusetts [1]. - Investors who purchased Zenas BioPharma securities during its IPO on September 13, 2024, have until June 16, 2025, to seek lead plaintiff status [1][2]. - The lawsuit claims that Zenas BioPharma overstated its operational funding timeline, stating it could fund operations for 24 months instead of the actual 12 months disclosed later [3][4]. Group 2: Financial Impact - Zenas BioPharma sold over 13 million shares at $17.00 per share during its IPO [2]. - As of April 15, 2025, Zenas BioPharma's stock closed at $8.72, representing a decline of 48.7% from the IPO price [4]. Group 3: Legal Process and Representation - The Private Securities Litigation Reform Act of 1995 allows investors to seek lead plaintiff status if they have suffered losses related to the IPO [5]. - The lead plaintiff will represent the interests of all class members and can choose a law firm for litigation [5]. Group 4: About Robbins Geller - Robbins Geller Rudman & Dowd LLP is a prominent law firm specializing in securities fraud and shareholder litigation, having recovered over $2.5 billion for investors in 2024 alone [6]. - The firm has been ranked 1 in securing monetary relief for investors in securities class action cases for four out of the last five years [6].

Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against Zenas BioPharma, Inc. due to allegations of violations of federal securities laws related to misleading statements about the company's financial status and IPO funding [2][4]. Group 1: Legal Investigation - The law firm is encouraging investors who suffered losses in Zenas to contact them directly to discuss their legal options [1]. - A federal securities class action has been filed against Zenas, with a deadline of June 16, 2025, for investors to seek the role of lead plaintiff [2]. - The complaint alleges that Zenas materially overstated its ability to fund operations with existing cash and expected IPO proceeds, leading to misleading public statements [4]. Group 2: Class Action Details - The lead plaintiff in a class action is the investor with the largest financial interest who directs the litigation on behalf of the class [5]. - Any member of the class can move the court to serve as lead plaintiff or remain an absent class member without affecting their ability to share in any recovery [5]. Group 3: Additional Information - Faruqi & Faruqi encourages anyone with information regarding Zenas' conduct, including whistleblowers and former employees, to contact the firm [6].

Core Viewpoint - A class action securities lawsuit has been filed against Zenas BioPharma, Inc. due to alleged securities fraud affecting investors who purchased shares during the company's September 2024 initial public offering [1][2]. Group 1: Lawsuit Details - The lawsuit aims to recover losses for investors adversely affected by alleged securities fraud related to Zenas BioPharma's IPO [2]. - The complaint alleges that Zenas BioPharma materially overstated its ability to fund operations using existing cash and expected net proceeds from the IPO, leading to false and misleading public statements [3]. Group 2: Next Steps for Investors - Investors who suffered losses in Zenas BioPharma during the relevant time frame have until June 16, 2025, to request appointment as lead plaintiff, although participation does not require serving in this role [4]. - Class members may be entitled to compensation without any out-of-pocket costs or fees [4]. Group 3: Firm Background - Levi & Korsinsky, LLP has a strong track record in securing compensation for shareholders and is recognized as one of the top securities litigation firms in the United States [5].

Core Viewpoint - Zenas BioPharma, Inc. is facing a class action lawsuit due to allegations of materially false and misleading statements regarding its financial status and operational funding during its initial public offering in September 2024 [2]. Group 1: Allegations - The complaint claims that Zenas BioPharma overstated its ability to fund operations with existing cash and expected net proceeds from the IPO [2]. - It is alleged that the public statements made by the defendants were materially false and misleading throughout the relevant period [2]. Group 2: Class Action Details - The class period for the lawsuit includes shareholders who purchased ZBIO securities during the time of the IPO registration statement [1]. - Shareholders are encouraged to register for the class action by June 16, 2025, to potentially become lead plaintiffs [3]. - There is no cost or obligation for shareholders to participate in the case [3]. Group 3: Law Firm Information - The Gross Law Firm is a nationally recognized class action law firm dedicated to protecting investors' rights against deceit and fraud [4]. - The firm aims to ensure companies adhere to responsible business practices and seeks recovery for investors who suffered losses due to misleading statements [4].

SAN DIEGO, June 9, 2025 /PRNewswire/ -- Robbins Geller Rudman & Dowd LLP announces that purchasers or acquirers of Zenas BioPharma, Inc. (NASDAQ: ZBIO) securities pursuant and/or traceable to Zenas BioPharma's registration statement issued in connection with Zenas BioPharma's initial public offering (the "IPO") held on or around September 13, 2024, and were damaged thereby, have until June 16, 2025 to seek appointment as lead plaintiff of the Zenas BioPharma class action lawsuit. Captioned Buathongsri v. Ze ...

Core Viewpoint - Rosen Law Firm is reminding investors of Zenas BioPharma, Inc. about the upcoming lead plaintiff deadline in a securities class action related to the company's IPO in September 2024 [1][5] Group 1: Class Action Details - Investors who purchased Zenas BioPharma securities may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2] - A class action lawsuit has already been filed, and interested parties must move the Court to serve as lead plaintiff by June 16, 2025 [3] - The lawsuit alleges that the Registration Statement contained false and misleading statements regarding the company's financial status and operational funding [5] Group 2: Rosen Law Firm's Credentials - Rosen Law Firm emphasizes the importance of selecting qualified legal counsel with a successful track record in securities class actions [4] - The firm has achieved significant settlements, including the largest securities class action settlement against a Chinese company at the time, and has recovered hundreds of millions for investors [4] - In 2019, the firm secured over $438 million for investors, showcasing its effectiveness in litigation [4]

Core Viewpoint - Zenas BioPharma, Inc. is facing a class action lawsuit due to allegations of misleading information in its IPO registration statement, particularly regarding the funding timeline for its operations [1][3][4]. Group 1: Class Action Lawsuit Details - The class action lawsuit is titled Buathongsri v. Zenas BioPharma, Inc. and was filed in the District of Massachusetts [1]. - Investors who purchased Zenas BioPharma securities during its IPO on September 13, 2024, have until June 16, 2025, to seek lead plaintiff status [1][2]. - The lawsuit claims that Zenas BioPharma overstated its operational funding timeline, stating it could fund operations for 24 months instead of the actual 12 months disclosed later [3][4]. Group 2: Financial Impact - Zenas BioPharma sold over 13 million shares at $17.00 per share during its IPO [2]. - As of April 15, 2025, Zenas BioPharma's stock closed at $8.72, representing a 48.7% decline from the IPO price [4]. Group 3: Legal Representation - Robbins Geller Rudman & Dowd LLP is representing the investors in the class action lawsuit and is recognized as a leading law firm in securities fraud litigation [6]. - The firm has a strong track record, having recovered over $2.5 billion for investors in 2024 alone [6].

Core Viewpoint - Rosen Law Firm is reminding investors of Zenas BioPharma, Inc. about a class action lawsuit related to the company's IPO, with a lead plaintiff deadline set for June 16, 2025 [1][5]. Group 1: Class Action Details - Investors who purchased Zenas BioPharma securities may be eligible for compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - A class action lawsuit has already been filed, and interested parties can join by contacting Rosen Law Firm [3][6]. - The lawsuit alleges that the Registration Statement contained false and misleading statements regarding Zenas BioPharma's financial status and operational funding [5]. Group 2: Legal Representation - Rosen Law Firm emphasizes the importance of selecting qualified legal counsel with a proven track record in securities class actions [4]. - The firm has a history of successful settlements, including the largest securities class action settlement against a Chinese company at the time [4]. - Investors are advised that until a class is certified, they are not represented by counsel unless they retain one [7].